Study S001493

A Randomized Controlled Trial of Once-Weekly Semaglutide for Limiting Post-Smoking Cessation Weight Gain in Adult Smokers With Overweight/Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06173778
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 197
Start: 2024-04-23
Primary completion: 2028-05-25
Lead sponsor: The University of Texas Health Science Center, Houston
Conditions: Obesity; Overweight; Cigarette Smoking
Interventions: DRUG:semaglutide 2.4mg; DRUG:Placebo; DRUG:Nicotine Replacement Therapy (NRT, nicotine patch); BEHAVIORAL:Brief Smoking Cessation Counseling
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in Body Weight Percent [Baseline to Week 28]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004445	A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol. Yammine L, Contemporary clinical trials	2025	Protocol	PMID 40554081 DOI	cites ClinicalTrials.gov:NCT06173778; registry reference DERIVED:40554081